Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Use of parent drug and metabolite data in bioavailability assessment of a novel diltiazem HCl once-daily product.

Eradiri O, Midha KK.

Pharm Res. 1995 Dec;12(12):2071-4. No abstract available.

PMID:
8786992
3.

Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment.

Bialer M, Hadad S, Golomb G, Barel S, Samara E, Abu Salach O, Berkman N, Danenberg HD, Ben David J, Caron D, et al.

Biopharm Drug Dispos. 1994 Jan;15(1):45-52.

PMID:
8161715
4.

Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration.

Ishikura T, Nagai T, Sakai Y, Shishikura T, Ebisawa H, Machida Y.

Drug Des Deliv. 1986 Nov;1(2):151-6.

PMID:
3509328
5.
6.

PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.

Luckow V, Della Paschoa O.

Int J Clin Pharmacol Ther. 1997 Oct;35(10):418-25.

PMID:
9352390
7.
8.

[Diltiazem and drug interactions (1). Effects of co-administered drugs and methods of administration on the bioavailability of diltiazem].

Etoh A, Kohno K.

Yakugaku Zasshi. 1983 Apr;103(4):426-33. Japanese. No abstract available.

PMID:
6631672
9.

Comparative bioavailability of diltiazem in prolonged-release oral preparations.

Quiroga PA, Yuln GV, Palummo M, Cingolani A, Dall LL, Volonté MG.

Drug Dev Ind Pharm. 2001 Nov;27(10):1099-106.

PMID:
11794812
10.
11.

In vivo performance of controlled release pellets of diltiazem HCl.

Nisarur-ur-Rahman, K H Y, Jia Woei W.

Pak J Pharm Sci. 2005 Apr;18(2):44-8.

PMID:
16431398
12.

A study comparing biopharmaceutic characteristics of four once daily controlled release diltiazem preparations.

Hendriks MG, Dogterom P, Ebels JT, Oosterhuis B, Geertsema LR, Hulot T, Bianchetti G, Jonkman JH.

Fundam Clin Pharmacol. 1998;12(5):559-65.

PMID:
9794155
13.

[Diltiazem and drug interactions (2). Effect of co-administered diltiazem on bioavailability of propranolol].

Etoh A, Kohno K, Shimizu T.

Yakugaku Zasshi. 1983 Apr;103(4):434-41. Japanese. No abstract available.

PMID:
6631673
14.
15.
16.

Diltiazem disposition and metabolism in recipients of renal transplants.

Morris RG, Jones TE.

Ther Drug Monit. 1998 Aug;20(4):365-70.

PMID:
9712457
17.
18.
19.

Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.

Scheiwe MW, Lankhaar G, Kleinbloesem CH.

Arzneimittelforschung. 1996 Oct;46(10):960-3.

PMID:
8931888
20.

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD.

Drug Metab Dispos. 2009 Aug;37(8):1587-97. doi: 10.1124/dmd.109.026658. Epub 2009 May 6.

Supplemental Content

Support Center